Method and composition for inhibiting cancer cell growth

• US 7,264,800 B2
• Filed: 01/27/2005
• Issued: 09/04/2007
• Est. Priority Date: 07/18/2002
• Status: Active Grant

• Current Assignee: Helix Biopharma Corp
• Original Assignee: Helix Biopharma Corp
• Inventors: Segal, Donald, Chao, Heman, Wong, Wah Y., McElroy, Jerry, Docherty, John, Dickstein, Jodi
• Primary Examiner(s): Wax; Robert A.
• Application Number:
  US11/046,271
• Publication Number:
  US 20050196391A1
• Time in Patent Office: 950 Days
• Field of Search: None
• US Class Current: 424/94.6
• CPC Class Codes: A61K 38/50 acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
• CPC Class Codes: A61K 47/66 the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
• CPC Class Codes: A61K 47/6815 Enzymes
• CPC Class Codes: A61K 47/6845 the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
• CPC Class Codes: A61K 47/6851 the antibody targeting a determinant of a tumour cell
• CPC Class Codes: A61K 47/6891 Pre-targeting systems involving an antibody for targeting specific cells
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

Improvements in methods of treating cancer with weakly basic anti-cancer compounds are provided. In one aspect, the invention provides an improvement in a method of treating cancer cells whose extracellular environment contains 1–8 mM urea, by exposing the cells to a weakly basic anti-cancer compound which is effective in inhibiting the growth of the cells. The improvement includes (a) exposing the cells to a urease enzyme composition and, (b) by step (a), reducing the amount of anti-cancer compound required to produce a given extent of inhibition in the growth of the cells when the cells are exposed to the anti-cancer agent. Methods of potentiating the specific therapeutic activity of a weakly basic anti-cancer compound in the treatment of a given mammalian cancer which is responsive to the compound are provided as are pharmaceutical compositions for use in intravenous administration to a subject are also provided.

Claims

1. In a method of treating cancer cells whose extracellular environment contains 1–

8 mM urea, by exposing said cells to a weakly basic anti-cancer compound which is effective in inhibiting the growth of said cells, an improvement comprising

(a) exposing the cells to a composition containing a urease enzyme, and

(b) by step (a), reducing the amount of said anti-cancer compound required to produce a given extent of inhibition in the growth of said cells, when the cells are exposed to the anti-cancer agent.

2. The improvement of claim 1, wherein said exposing is effective to raise the pH of the extracellular environment of the cancer cells by at least 0.1 pH unit.

3. The improvement of claim 2, wherein said anti-cancer compound is selected from the group consisting of doxorubicin, daunorubicin, mitoxantrone, epirubicin, mitomycin, bleomycin, a vinca alkaloid, an alkylating agent, or an antineoplastic purine and pyrimidine derivative.

4. The improvement of claim 2, wherein the amount of said anti-cancer compound required to achieve the same extent of cell-growth inhibition is between about 2-fold and 5-fold less than in the absence of step (a).

5. The improvement of claim 2, wherein said composition includes a targeting moiety attached to said urease enzyme and selected from the group consisting of an antibody directed against a tumor antigen, an anti-hCG antibody, and a ligand capable of binding specifically to a cancer-cell surface receptor.

6. The improvement of claim 5, wherein said targeting moiety is a single-chain antibody.

7. The improvement of claim 2, in a method for treating a cancer in a mammalian subject, by administration of such anti-cancer compound to the subject, wherein step (a) includes administering to the subject, a urease composition effective to localize at the site of the cancer in the subject.

8. The improvement of claim 7, wherein said urease composition is administered intravenously in an amount of between 25 and 2000 pmoles urease enzyme/kg subject body weight, at least 24 hours prior to administration of the anti-cancer compound.

9. The improvement of claim 8, wherein said urease composition is administered by IV drip and the composition includes a urease inhibitor selected from the group consisting of a hydroxamic acid derivative and other urea analogs, in an amount effective inhibit the activity of the urease enzyme at the initial concentration of the urease composition.

10. The improvement of claim 7, for use in treating a solid tumor, wherein said urease composition is administered directly in the tumor in an amount effective to raise the pH total of the extracellular fluid of said tumor, as evidenced by detectable change in a pH indicator present in the tumor extracellular fluid.

11. A method of treating a cancer that is responsive to a selected weakly basic anti-tumor compound in mammalian subject, comprising:

administering to the subject, such weakly basic anti-cancer compound and an amount of a urease enzyme composition sufficient to potentiate the therapeutic effect of the compound with respect to the therapeutic effect obtained in the absence of said urease composition administration.

12. The method of claim 11, which includes administering said urease composition at least 24 hours prior to administering the anti-cancer compound.

13. The method of claim 11, which includes co-administering the anti-cancer compound and the urease composition.

14. The method of claim 11, wherein urease composition is administered in an amount effective to raise the pH of the extracellular environment of the cancer cells by at least 0.1 pH unit.

15. The method of claim 11, wherein administration of the urease composition is effective to reduce the amount of said anti-cancer compound required to achieve the same extent of cell-growth inhibition by a factor of between 2 and 5.

16. The method of claim 11, wherein said anti-cancer compound is selected from the group consisting of doxorubicin, daunorubicin, mitoxantrone, epirubicin, mitomycin, bleomycin, a vinca alkaloid, an alkylating agent, or an antineoplastic purine or pyrimidine derivative.

17. The method of claim 11, wherein said urease composition includes a targeting moiety attached to said urease and selected from the group consisting of an antibody directed against a tumor antigen, an anti-hCG antibody, and a ligand capable of binding specifically to an cancer-cell surface receptor.

18. The method of claim 11, wherein said urease composition is administered by IV drip in an amount of between 25 and 2000 pmoles urease enzyme/kg subject body weight, and the composition includes a urease inhibitor selected from the group consisting of a hydroxamic acid derivative and other urea analogs, in an amount effective to inhibit the activity of the urease enzyme at the initial concentration of the urease composition.

19. In a subject having a solid tumor a method of enhancing the therapeutic efficacy of a weakly basic anti-tumor compound whose effectiveness is reduced by a higher intracellular/lower extracellular pH gradient in a solid tumor, comprising administering to the subject receiving said anti-tumor compound, an amount of urease effective to reduce or reverse the higher intracellular/lower extracellular pH gradient in a solid tumor.

20. The method of claim 19, wherein said anti-tumor compound is selected from the group consisting of doxorubicin, dauorubicin, mitoxanthrone, epirubicin, mitomycin, bleomycin, vinca alkaloids, alkylating agents and antineoplastic purine and pyrimidine derivatives.

21. The method of claim 19, wherein said administering is effective to raise the extracellular fluid of the tumor of at least pH 7.2.

22. The method of claim 19, wherein said administering includes injecting urease directly into the subject'"'"'s tumor.

23. The method of claim 19, wherein said urease is administered parenterally other than by direct injection in a composition that includes a chemical entity effective to enhance the delivery of the enzyme to a solid tumor.

24. The method of claim 20, wherein the vinca alkaloid is selected from the group consisting of vinblastine and vincristine.

25. The method of claim 20, wherein the alkylating agent is selected from the group consisting of cyclophosphamide and mechlorethamine hydrochloride.